Table 2. Effect of atorvastatin treatment on levels of cholesterol and immune mediators.

Parameter		Placebo (median) [IQR]		Atorvastatin (median) [IQR]
Total cholesterol (mmol/l)	At baseline	4.02 [1.03]	n.s.	3.93 [0.96]	p<0.0001
	At 3 months	3.89 [1.13]		2.56 [0.78]
CRP (mg/l)	At baseline	0.84 [2.24]	n.s.	0.86 [2.17]	p = 0.029
	At 3 months	0.64 [1.41]		0.69 [1.07]
IL-6 (pg/ml)	At baseline	0.58 [0.54]	n.s.	0.75 [1.08]	n.s.
	At 3 months	0.67 [0.50]		0.56 [1.62]
Cholesterol above baseline median	At baseline	4.53 [0.70]	n.s.	4.33 [0.57]	p<0.0001
	At 3 months	4.44 [0.96]		2.94 [0.61]
Cholesterol below baseline median	At baseline	3.57 [0.39]	n.s.	3.39 [0.69]	p<0.0001
	At 3 months	3.47 [0.63]		2.35 [0.76]
CRP above baseline median	At baseline	2.55 [2.75]	n.s.	2.37 [1.90]	p = 0.037
	At 3 months	1.73 [3.39]		1.24 [0.86]
CRP below baseline median	At baseline	0.33 [0.23]	n.s.	0.24 [0.40]	n.s.
	At 3 months	0.36 [0.31]		0.21 [0.34]